Breaking News

Study: Many poor countries where experimental drugs are tested fail to benefit after approval

November 17, 2025
Pharmalot Columnist, Senior Writer
Adobe

STAT+ | Many poor countries where experimental drugs are tested fail to benefit after approval, analysis finds

JAMA study shows that among 144 drugs tested outside the U.S., only 24%were physically accessible in those countries after the drug was approved.

By Ed Silverman


STAT+ | China's WuXi AppTec, after evading threat of U.S. restrictions, comes out ahead

Sales up 31.9% as Chinese contract research giant with extensive ties to American biopharma dodges national security effort to restrict its U.S. operations.

By Brian Yang


STAT+ | Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology

The deal is the first major buyout for a startup built around so-called PROTACs, a field that has attracted big investment but not yet secured approvals.  

By Jason Mast



Adobe

STAT+ | Opinion: Sanofi CEO: How we're measuring AI success

Paul Hudson, CEO of Sanofi, describes how his company is measuring return on investment for AI, or ROAI.

By Paul Hudson


STAT+ | Nuvalent sees success for its second genetically targeted lung cancer drug

ALK+ lung cancer is a dramatic example of how targeting certain enzymes in tumors can produce dramatic results

By Matthew Herper


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments